• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Karuna, Cerevel might be just the start of psychiatry drug M&A

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 23, 2024 at 11:32: AM
via With two biotech buyouts, schizophrenia drugs appear back on pharma’s radar. Deal documents suggest others besides Bristol Myers and AbbVie may be looking.

article source
 

<



Similar threads

cafead
Do Karuna, Cerevel Deals Signal Renewed Neuropsychiatric Interest From Big Pharma?
Replies
0
Views
26
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
As BMS announces major cuts, its Karuna deal looks poised to drive growth
Replies
0
Views
220
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Karuna&#039;s captains set sail in new neuropsychiatric venture called Seaport Therapeutics
Replies
0
Views
123
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS won out against other pharmas in bid for RayzeBio, just days after competing for Karuna
Replies
0
Views
150
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Another big pharma competed for Karuna, submitting all-cash offer day before BMS deal...
Replies
0
Views
232
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote